Intercept Drug’s Market Standing In PBC Undermined By Safety Woes

Ocaliva Now Contraindicated In Advanced Cirrhosis

A second FDA safety labeling update for Intercept’s Ocaliva might open a market opportunity in second-line PBC for Phase III candidates at CymaBay and Genfit.

liver
Two FDA safety updates for PBC drug Ocaliva could threaten its market standing

Given its setbacks this past year in non-alcoholic steatohepatitis, Intercept Pharmaceuticals, Inc.’s sales performance with primary biliary cholangitis drug Ocaliva (obeticholic acid/OCA) has gained importance. A US Food and Drug Administration labeling update on 26 May contraindicating the drug in PBC patients with advanced cirrhosis may dampen those revenue prospects while opening a market opportunity for a pair of Phase III candidates being studied by competitors as second-line PBC therapies.

Intercept also is developing OCA, an FXR agonist, as a potential treatment for NASH; the company received a complete response...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.